Abstract: Citraconic acid (CA) or derivative thereof for use as medicament, for example in the treatment of a medical condition associated with inflammation. In another aspect, the invention relates to a citraconic acid derivative according to formulae 1-XIII. In another aspect, the invention relates to a pharmaceutical composition comprising citraconic acid or derivative thereof with one or more pharmaceutical excipients for use in the treatment of a medical condition, such as those associated with inflammation and/or a non-inflammation associated medical condition.

Abstract: There is provided a method of obtaining selecting agents which inhibit the enzyme glucose-1-phosphate thymidylyltransferase (Rm1A) based upon analysis of a model of the active and regulatory site (s) of Rm1A and interaction therewith by a potential inhibitory agent. The invention is based upon the provision of information on the structure of Rm1A obtained through X-ray diffraction studies since a crystallised form of Rm1A was obtained for the first time. The purified and crystallised from of Rm1A, obtained from Psemdomononas aeruginosa is also described.